 MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market MNOV and the JASDAQ Market of the Tokyo Stock Exchange Code Number: 4875, today announced that it will initiate a clinical trial of MN-166 ibudilast for acute respiratory distress syndrome ARDS caused by COVID-19 Coronavirus Disease 2019. The study will be conducted by Yales Advanced Therapies Group, which is co-directed by Richard Bucala, M.D., Ph.D., Chief, Rheumatology, Allergy Immunology at Yale School of Medicine and Rheumatologist-in-Chief at Yale New Haven Health. 